ArticleFrontiers in immunology2026
Identification of a migrasome-related lncRNA signature and its prognostic and immunological role in bladder cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic insights into the lncRNA-Notch signaling axis in tumors.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BLCA) is a highly heterogeneous malignancy with considerable variability in clinical outcomes. Reliable biomarkers for prognosis and treatment guidance remain urgently needed. Migrasomes, recently identified cellular organelles involved in intercellular communication, have been implicated in cancer progression, yet their associated long non-coding RNAs (lncRNAs) and prognostic relevance in BLCA remain unclear. Methods: We integrated transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) to identify migrasome-related lncRNAs through co-expression analysis. A prognostic signature was constructed using univariate Cox, LASSO, and multivariate regression analyses. Patients were stratified into high- and low-risk groups across training, validation, and entire cohorts. Kaplan-Meier survival, ROC curves, PCA, and Cox analyses were used for validation. Functional annotation was conducted via GO, KEGG, and GSEA. Immune infiltration and tumor microenvironment features were evaluated using ESTIMATE and CIBERSORT, while tumor mutation burden (TMB), immune escape potential, and drug sensitivity were also analyzed. Single-cell RNA sequencing (scRNA-seq) analysis delineated cellular heterogeneity and intercellular communication patterns related to the risk signature in the BLCA microenvironment. Finally, experimental validation of SEC24B-AS1, a key lncRNA within the model, was performed through qRT-PCR, CCK-8, colony formation, and migration assays to confirm its biological relevance. Results: A robust prognostic signature comprising migrasome-related lncRNAs was established, effectively distinguishing patients into high- and low-risk groups with significantly different survival outcomes. The signature remained an independent prognostic factor after multivariate adjustment. Functional enrichment analyses revealed marked biological distinctions between the two groups. Immune profiling showed higher immune and stromal scores in high-risk patients, together with distinct immune cell composition and function. High-risk tumors also exhibited elevated TMB and increased immune evasion potential. Drug sensitivity analysis identified compounds with differential responses between risk subgroups. Single-cell transcriptomic analysis indicated that the signature reflects cellular heterogeneity and intercellular communication patterns within the BLCA microenvironment. Experimental validation of SEC24B-AS1, a key lncRNA in the model, demonstrated its impact on tumor cell proliferation and migration, supporting the biological relevance of the prognostic signature in BLCA. Conclusion: This study presents a novel migrasome-related lncRNA signature that independently predicts survival in bladder cancer and reflects the tumor immune landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.